Voyageur Pharmaceuticals Ltd. (VM.V)
CAD 0.11
(50.0%)
CAD 0.11
(50.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.22 Million CAD | 30.23% |
| 2022 | -1.74 Million CAD | 14.7% |
| 2021 | -2.05 Million CAD | -141.65% |
| 2020 | -848.93 Thousand CAD | -52.99% |
| 2019 | -554.89 Thousand CAD | 51.72% |
| 2018 | -1.14 Million CAD | -86.77% |
| 2017 | -615.36 Thousand CAD | -1076.09% |
| 2016 | -52.32 Thousand CAD | -3430.57% |
| 2015 | -1482.00 CAD | 98.43% |
| 2014 | -94.46 Thousand CAD | -108.4% |
| 2013 | -45.32 Thousand CAD | 47.0% |
| 2012 | -85.51 Thousand CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -561.9 Thousand CAD | -70.82% |
| 2024 Q1 | -328.95 Thousand CAD | -43.5% |
| 2024 Q3 | -359.13 Thousand CAD | 36.09% |
| 2023 Q2 | -621.48 Thousand CAD | -66.31% |
| 2023 Q3 | -130.69 Thousand CAD | 78.97% |
| 2023 FY | -1.34 Million CAD | 23.06% |
| 2023 Q4 | -229.24 Thousand CAD | -75.41% |
| 2023 Q1 | -373.69 Thousand CAD | 34.76% |
| 2022 Q3 | -426.82 Thousand CAD | 10.43% |
| 2022 Q1 | -247.35 Thousand CAD | 52.23% |
| 2022 Q2 | -476.51 Thousand CAD | -92.65% |
| 2022 Q4 | -572.8 Thousand CAD | -34.2% |
| 2022 FY | -1.74 Million CAD | 14.7% |
| 2021 Q1 | -79.91 Thousand CAD | 52.55% |
| 2021 FY | -2.05 Million CAD | -141.65% |
| 2021 Q4 | -517.82 Thousand CAD | -40.3% |
| 2021 Q2 | -327.2 Thousand CAD | -309.46% |
| 2021 Q3 | -369.08 Thousand CAD | -12.8% |
| 2020 Q4 | -168.42 Thousand CAD | -26.16% |
| 2020 Q3 | -133.5 Thousand CAD | 49.61% |
| 2020 Q1 | -408.64 Thousand CAD | -354.01% |
| 2020 FY | -848.93 Thousand CAD | -52.99% |
| 2020 Q2 | -264.93 Thousand CAD | 35.17% |
| 2019 Q2 | -108.1 Thousand CAD | 24.7% |
| 2019 Q4 | -90 Thousand CAD | 57.79% |
| 2019 Q3 | -213.21 Thousand CAD | -97.24% |
| 2019 FY | -554.89 Thousand CAD | 51.72% |
| 2019 Q1 | -143.56 Thousand CAD | 36.02% |
| 2018 FY | -1.14 Million CAD | -86.77% |
| 2018 Q1 | -141.35 Thousand CAD | -70.0% |
| 2018 Q2 | -154.77 Thousand CAD | -9.49% |
| 2018 Q3 | -628.79 Thousand CAD | -306.28% |
| 2018 Q4 | -224.4 Thousand CAD | 64.31% |
| 2017 Q1 | -45.31 Thousand CAD | -49.63% |
| 2017 Q3 | -220.05 Thousand CAD | 17.54% |
| 2017 FY | -615.36 Thousand CAD | -1076.09% |
| 2017 Q4 | -83.15 Thousand CAD | 62.21% |
| 2017 Q2 | -266.84 Thousand CAD | -488.93% |
| 2016 Q1 | -1092.00 CAD | 89.67% |
| 2016 Q2 | -15.45 Thousand CAD | -1315.11% |
| 2016 Q3 | -5496.00 CAD | 64.43% |
| 2016 Q4 | -30.28 Thousand CAD | -450.98% |
| 2016 FY | -52.32 Thousand CAD | -3430.57% |
| 2015 Q1 | -4025.00 CAD | 86.57% |
| 2015 FY | -1482.00 CAD | 98.43% |
| 2015 Q4 | -10.56 Thousand CAD | -1185.77% |
| 2015 Q2 | 16.86 Thousand CAD | 518.88% |
| 2015 Q3 | -822.00 CAD | -104.88% |
| 2014 Q1 | -5945.00 CAD | 82.45% |
| 2014 FY | -94.46 Thousand CAD | -108.4% |
| 2014 Q4 | -29.96 Thousand CAD | -213.65% |
| 2014 Q3 | -9552.00 CAD | 80.51% |
| 2014 Q2 | -49 Thousand CAD | -724.27% |
| 2013 Q3 | -1854.00 CAD | 49.69% |
| 2013 Q4 | -33.86 Thousand CAD | -1726.81% |
| 2013 Q2 | -3685.00 CAD | 37.74% |
| 2013 Q1 | -5919.00 CAD | 74.34% |
| 2013 FY | -45.32 Thousand CAD | 47.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q4 | -23.07 Thousand CAD | -26.04% |
| 2012 FY | -85.51 Thousand CAD | 0.0% |
| 2012 Q2 | -44.14 Thousand CAD | 0.0% |
| 2012 Q3 | -18.3 Thousand CAD | 58.54% |
| 2011 FY | - CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | -2.82 Million CAD | 56.708% |
| CanadaBis Capital Inc. | 4.67 Million CAD | 126.106% |
| Decibel Cannabis Company Inc. | 1.41 Million CAD | 186.47% |
| Delivra Health Brands Inc. | -710 Thousand CAD | -71.965% |
| Entourage Health Corp. | -21.37 Million CAD | 94.289% |
| Lifeist Wellness Inc. | -12.24 Million CAD | 90.033% |
| Cannara Biotech Inc. | 11.88 Million CAD | 110.271% |
| Medicure Inc. | -854 Thousand CAD | -42.969% |
| PharmaCielo Ltd. | -9.7 Million CAD | 87.414% |
| Rubicon Organics Inc. | -1.08 Million CAD | -12.692% |
| BioSyent Inc. | 7.47 Million CAD | 116.342% |